The proteasome and proteasome inhibitors in multiple myeloma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Metastasis Review

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10555-017-9707-8PMID 29196868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current treatment options and investigational drugs for Waldenstrom’s Macroglobulinemia

  2017cited by this paper
• Bortezomib resistance in multiple myeloma is associated with increased serine synthesis

  2017cited by this paper
• Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors

  2017cited by this paper
• Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials

  2017cited by this paper
• Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)

  2017cited by this paper
• Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance

  2017cited by this paper
• Genomic complexity of multiple myeloma and its clinical implications

  2017cited by this paper
• Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

  2017cited by this paper
• Proteasome inhibitor-induced gastrointestinal toxicity

  2017cited by this paper
• New and developing therapies for AL amyloidosis

  2017cited by this paper
• Proteasome Inhibitors as a Potential Cause of Heart Failure.

  2017cited by this paper
• Cardiac and renal complications of carfilzomib in patients with multiple myeloma.

  2017cited by this paper
• The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685)

  2017cited by this paper
• A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

  2017cited by this paper
• A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma

  2017cited by this paper
• Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

  2017cited by this paper
• Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

  2017cited by this paper
• Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

  2017cited by this paper
• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

  2017cited by this paper
• Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

  2017cited by this paper
• Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study

  2017cited by this paper
• Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

  2017cited by this paper
• An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

  2017cited by this paper
• Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management

  2017cited by this paper
• Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cited by this paper
• Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

  2017cited by this paper
• Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

  2017cited by this paper
• A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

  2017cited by this paper
• Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

  2017cited by this paper
• Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

  2017cited by this paper
• Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: A meta-analysis of phase III randomized controlled trials.

  2017cited by this paper
• Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

  2017cited by this paper
• Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.

  2016cited by this paper
• Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

  2016cited by this paper
• Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

  2016cited by this paper
• Are maintenance and continuous therapies indicated for every patient with multiple myeloma?

  2016cited by this paper
• Dual Carfilzomib and Doxorubicin–Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma

  2016cited by this paper
• The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

  2016cited by this paper
• Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.

  2016cited by this paper
• A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

  2016cited by this paper
• Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

  2016cited by this paper
• MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.

  2016cited by this paper
• Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

  2016cited by this paper
• Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

  2016cited by this paper
• Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

  2016cited by this paper
• Identification of new SUMO activating enzyme 1 inhibitors using virtual screening and scaffold hopping.

  2016cited by this paper
• ‘Real‐life’ experience of preapproval carfilzomib‐based therapy in myeloma – analysis of cardiac toxicity and predisposing factors

  2016cited by this paper
• Progress and Paradigms in Multiple Myeloma

  2016cited by this paper
• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

  2016cited by this paper
• Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

  2016cited by this paper
• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.

  2016cited by this paper
• Drugging the undruggables: exploring the ubiquitin system for drug development

  2016cited by this paper
• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

  2016cited by this paper
• Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.

  2016cited by this paper
• Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results

  2016cited by this paper
• VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

  2016cited by this paper
• Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study

  2016cited by this paper
• Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

  2016cited by this paper
• VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

  2016cited by this paper
• Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

  2016cited by this paper
• Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

  2016cited by this paper
• Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

  2016cited by this paper
• A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

  2016cited by this paper
• Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

  2016cited by this paper
• Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

  2016cited by this paper
• NF-κB dysregulation in multiple myeloma.

  2016cited by this paper
• Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study

  2016cited by this paper
• Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

  2016cited by this paper
• Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

  2015cited by this paper
• Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

  2015cited by this paper
• Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

  2015cited by this paper
• Molecular basis of resistance to proteasome inhibitors in hematological malignancies.

  2015cited by this paper
• Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis

  2015cited by this paper
• Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

  2015cited by this paper
• Synergistic anti‐myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide

  2015cited by this paper
• Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

  2015cited by this paper
• Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy

  2015cited by this paper
• Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2

  2015cited by this paper
• Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

  2015cited by this paper
• Multiple myeloma

  2015cited by this paper
• When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response

  2015cited by this paper
• Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

  2015cited by this paper
• Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

  2015cited by this paper
• Current treatment landscape for relapsed and/or refractory multiple myeloma

  2015cited by this paper
• Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.

  2015cited by this paper
• Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

  2015cited by this paper
• Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment

  2015cited by this paper
• Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

  2015cited by this paper
• Targeting ubiquitination for cancer therapies.

  2015cited by this paper
• Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib

  2015cited by this paper
• Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies

  2015cited by this paper
• A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

  2015cited by this paper
• Deubiquitinases (DUBs) and DUB inhibitors: a patent review

  2015cited by this paper
• Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.

  2015cited by this paper
• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

  2015cited by this paper
• Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

  2015cited by this paper

• Carfilzomib-induced sinus bradycardia: A case report and literature review

  2026cites this paper
• Pharmacovigilance-Based Safety Profile of Bortezomib: A Disproportionality Analysis Using FAERS Data

  2026cites this paper
• APRIL-driven BCMA/TACI dual-targeted ligand–drug conjugates for selective and potent therapy of multiple myeloma

  2026cites this paper
• Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma

  2026cites this paper
• A bortezomib resistance–related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma

  2026cites this paper
• Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study.

  2026cites this paper
• Hemoglobin as a Molecular Glue: Toward Potent Inhibition of HbS Polymerization in Sickle Cell Disease.

  2026cites this paper
• Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms.

  2026cites this paper
• Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities

  2025cites this paper
• An in vivo imaging approach for simultaneously assessing tumor response and cytotoxicity-induced tissue response in chemotherapy

  2025cites this paper
• Exploration of genes related to the development of cancer of unknown primary

  2025cites this paper
• Modulators of the ubiquitin-proteasome system from natural products: chemical structures and their potential for drug discovery.

  2025cites this paper
• High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

  2025cites this paper
• Synergistic Mechanisms of Traditional Chinese Medicine and Proteasome Inhibitors in Multiple Myeloma Therapy: A Comprehensive Review

  2025cites this paper
• Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma

  2025cites this paper
• Targeting the Ubiquitin–Proteasome System for Cancer

  2025cites this paper
• Comprehensive bioinformatics analysis reveals key hub genes linked to prognosis in multiple myeloma with drug resistance

  2025cites this paper
• Ligand-based cheminformatics and free energy-inspired molecular simulations for prioritizing and optimizing G-protein coupled receptor kinase-6 (GRK6) inhibitors in multiple myeloma treatment

  2025cites this paper
• Exploring research advances and future trends in drug resistance in multiple myeloma: A comprehensive bibliometric analysis

  2025cites this paper
• Cancer Drug Bortezomib, a Proteasomal Inhibitor, Triggers Cytotoxicity in Microvascular Endothelial Cells via Multi-Organelle Stress

  2025cites this paper
• Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma

  2025cites this paper
• Antitumor effect of BC12-3 on multiple myeloma via proteasome inhibition

  2025cites this paper
• Tumor Microenvironment: Current Understanding and Therapeutic Implications in Adult and Pediatric Cancers

  2025cites this paper
• Curcumin modulates β-catenin stabilization via targeting proteasomal deubiquitinating enzyme USP14.

  2025cites this paper
• Identification of a new micropeptide altKLF4 derived from KLF4 that influences myeloma chemotherapeutic sensitivity.

  2025cites this paper
• Investigation of the effects of small VCP-interacting protein (SVIP)on the migration and invasion of breast cancer cells.

  2025cites this paper
• Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients

  2025cites this paper
• First-in-Class Potent, Dual HDAC6/Proteasome Inhibitors Lacking a Hydroxamic Acid Motif: Discovery of Novel Anti-Multiple Myeloma Agents.

  2025cites this paper
• UBA protein family: An emerging set of E1 ubiquitin ligases in cancer-A review.

  2025cites this paper
• Targeting proteostasis for cancer therapy: current advances, challenges, and future perspectives

  2025cites this paper
• Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma

  2025cites this paper
• Discovery of RGS2-FBXO44 interaction inhibitors using a cell-based NanoBit assay.

  2025cites this paper
• Role of YY1 in pancreatic ductal adenocarcinoma: Mechanisms and therapeutic perspectives.

  2025cites this paper
• Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.

  2025cites this paper
• Boanmycin overcomes bortezomib resistance by inducing DNA damage and endoplasmic reticulum functional impairment in multiple myeloma

  2025cites this paper
• Proteasome stress activates YAP/TAZ through the RAP2-MAP4Ks-LATS1/2 pathway and its therapeutic implications in solid tumors.

  2025cites this paper
• Targeting Caseinolytic Mitochondrial Matrix Peptidase, a Novel Contributor to High-risk Behavior, in Multiple Myeloma.

  2025cites this paper
• Time-performance relationship and the associated mechanism of tumor drug-efflux pump P-glycoprotein reversal induced by mild photothermal therapy.

  2025cites this paper
• Bortezomib-loaded hybrid liposome inducing pyroptosis for targeted therapy against colorectal cancer

  2025cites this paper
• A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis

  2025cites this paper
• Tumor microenvironment as a novel therapeutic target for lymphoid leukemias

  2025cites this paper
• Progress of immune senescence in multiple myeloma treatment resistance

  2025cites this paper
• Desensitization in HLA-incompatible kidney transplant recipients: current strategies and emerging perspectives

  2025cites this paper
• Unlocking the Therapeutic Potential of Algae-Derived Compounds in Hematological Malignancies

  2025cites this paper
• Exploiting the cardioprotective potential of metformin against cardiotoxic agents

  2025cites this paper
• Nitro-fatty acids: promising agents for the development of new cancer therapeutics.

  2024cites this paper
• [Application of high-throughput drug sensitivity testing in children with relapsed and refractory acute leukemia].

  2024cites this paper
• miR-326 overexpression inhibits colorectal cancer cell growth and proteasome activity by targeting PNO1: unveiling a novel therapeutic intervention strategy

  2024cites this paper
• Deubiquitinase PSMD7 facilitates pancreatic cancer progression through activating Nocth1 pathway via modifying SOX2 degradation

  2024cites this paper
• Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A review

  2024cites this paper
• Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib

  2024cites this paper
• Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions.

  2024cites this paper
• Proteasome inhibitors FHND6091 enhance the ability of NK cells to kill tumor cells through multiple mechanisms.

  2024cites this paper
• Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

  2024cites this paper
• Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms

  2024cites this paper
• PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling

  2024cites this paper
• Temperature Self-Limited Intelligent Thermo-chemotherapeutic Lipid Nanosystem for P-gp Reversal Time Window Matched Pulse Treatment of MDR Tumor.

  2024cites this paper
• Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma

  2024cites this paper
• BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma

  2024cites this paper
• PSME3 promotes lung adenocarcinoma development by regulating the TGF-β/SMAD signaling pathway

  2024cites this paper
• MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells

  2024cites this paper
• PRAME promotes proliferation of multiple myeloma cells through CTMP/Akt/p21/CCND3 axis by ubiquitinating CTMP and p21

  2024cites this paper
• B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer

  2024cites this paper
• An evolutionarily conserved ubiquitin ligase drives infection and transmission of flaviviruses

  2024cites this paper
• Exploring paraptosis as a therapeutic approach in cancer treatment

  2024cites this paper
• MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis

  2024cites this paper
• Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma

  2024cites this paper
• A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models

  2024cites this paper
• Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

  2024influential citation
• Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma

  2024cites this paper
• Proteasome inhibitor‐associated histiocytoid Sweet's syndrome: Clinical and histological similarities to Nakajo‐Nishimura syndrome suggest a potential mechanism

  2024cites this paper
• Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma.

  2024cites this paper
• Development of Proteasome Inhibitors for Cancer Therapy

  2024cites this paper
• A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients

  2024cites this paper
• The Efficacy of Carfilzomib Treatment in Bortezomib-Refractory Patients—Real Life Experience in a Tertiary Romanian Hospital

  2024cites this paper
• Treatment of multiple myeloma: What is the impact on T-cell function?

  2024cites this paper
• Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis

  2024cites this paper
• Lessons learned from phenotypic drug discovery efforts

  2024cites this paper
• Cytotoxic Effects of the Combination of Pam3CSK4 with Carfilzomib, Ixazomib, and Venetoclax in Human Multiple Myeloma Cells

  2024cites this paper
• Integral Solvent-Induced Protein Precipitation for Target-Engagement Studies in Plasmodium falciparum

  2024cites this paper
• Deguelin inhibits the proliferation of human multiple myeloma cells by inducing apoptosis and G2/M cell cycle arrest: Involvement of Akt and p38 MAPK signalling pathway

  2024cites this paper
• From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

  2024cites this paper
• Disruption of Proteostasis by Natural Products and Synthetic Compounds That Induce Pervasive Unfolding of Proteins: Therapeutic Implications

  2023cites this paper
• Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives

  2023cites this paper
• A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling

  2023cites this paper
• Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome

  2023cites this paper
• The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma

  2023cites this paper
• Exploration of novel four-membered-heterocycle constructed peptidyl proteasome inhibitors with improved metabolic stability for cancer treatment.

  2023cites this paper
• Recent advances and future perspectives of noncompetitive proteasome inhibitors.

  2023cites this paper
• Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse

  2023cites this paper
• High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex

  2023cites this paper
• Targeting plasma cells in systemic autoimmune rheumatic diseases - promises and pitfalls.

  2023cites this paper
• Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma

  2023cites this paper
• New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers.

  2023cites this paper
• High-Throughput Assay for Characterizing Rpn11 Deubiquitinase Activity.

  2023cites this paper
• Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

  2023cites this paper
• Withaferin A and Celastrol Overwhelm Proteostasis

  2023cites this paper
• An impaired ubiquitin-proteasome system increases APOBEC3A abundance

  2023cites this paper
• Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease

  2023cites this paper
• Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy

  2023cites this paper